U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C24H19ClN4O4
Molecular Weight 462.885
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BMS-908662

SMILES

COC(=O)NC1=NC2=C(N1)C=CC(=C2)C3(O)N(C(=O)C4=CC=CC=C34)C5=C(C)C=CC(Cl)=C5

InChI

InChIKey=MMNNTJYFHUDSKL-UHFFFAOYSA-N
InChI=1S/C24H19ClN4O4/c1-13-7-9-15(25)12-20(13)29-21(30)16-5-3-4-6-17(16)24(29,32)14-8-10-18-19(11-14)27-22(26-18)28-23(31)33-2/h3-12,32H,1-2H3,(H2,26,27,28,31)

HIDE SMILES / InChI

Molecular Formula C24H19ClN4O4
Molecular Weight 462.885
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

BMS-908662 (previously known as XL281) is a small molecule Raf kinase inhibitor that lies immediately downstream of RAS and are key components of the RAS/RAF/MEK/ERK kinase-signaling pathway. Bristol-Myers Squibb has received an exclusive worldwide license to develop and commercialize antineoplastic agent XL281. BMS-908662 participated in phase I development for the treatment of patients with melanoma and in combination with cetuximab for patients with colorectal cancer. However, further, development has been discontinued.

Approval Year

PubMed

PubMed

TitleDatePubMed
Phase I study of XL281 (BMS-908662), a potent oral RAF kinase inhibitor, in patients with advanced solid tumors.
2015-04
Clinico-morphological features of BRAF inhibition-induced proliferative skin lesions in cancer patients.
2015-01-01
Paradoxical activation of T cells via augmented ERK signaling mediated by a RAF inhibitor.
2014-01
Patents

Sample Use Guides

Capsules, Oral, escalating doses starting at 25 mg, every 12 hours (Q 12 h), Continuously
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:18:17 GMT 2025
Edited
by admin
on Mon Mar 31 18:18:17 GMT 2025
Record UNII
DW2NWI3TFN
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BMS-908662
Common Name English
BMS-908662 FREE BASE
Preferred Name English
CARBAMIC ACID, N-(6-(2-(5-CHLORO-2-METHYLPHENYL)-2,3-DIHYDRO-1-HYDROXY-3-OXO-1H-ISOINDOL-1-YL)-1H-BENZIMIDAZOL-2-YL)-, METHYL ESTER
Common Name English
METHYL (5-(2-(5-CHLORO-2-METHYLPHENYL)-1-HYDROXY-3-OXO-2,3-DIHYDRO-1H-ISOINDOL-1-YL)-1H-BENZIMIDAZOL-2-YL)CARBAMATE
Systematic Name English
CARBAMIC ACID, (5-(2-(5-CHLORO-2-METHYLPHENYL)-2,3-DIHYDRO-1-HYDRO
Common Name English
(±)-METHYL (5-(2-(5-CHLORO-2-METHYLPHENYL)-1-HYDROXY-3-OXO-2,3-DIHYDRO-1H-ISOINDOL-1-YL)-1H-BENZIMIDAZOL-2-YL)CARBAMATE
Systematic Name English
METHYL (5-(2-(5-CHLORO-2-METHYLPHENYL)-1-HYDROXY-3-OXO-2,3-DIHYDRO-1H-ISOINDOL-1-YL)-1H-BENZIMIDAZOL-2-YL)CARBAMATE, (±)-
Systematic Name English
XL 281 [WHO-DD]
Common Name English
Code System Code Type Description
SMS_ID
100000174997
Created by admin on Mon Mar 31 18:18:17 GMT 2025 , Edited by admin on Mon Mar 31 18:18:17 GMT 2025
PRIMARY
FDA UNII
DW2NWI3TFN
Created by admin on Mon Mar 31 18:18:17 GMT 2025 , Edited by admin on Mon Mar 31 18:18:17 GMT 2025
PRIMARY
DRUG BANK
DB12854
Created by admin on Mon Mar 31 18:18:17 GMT 2025 , Edited by admin on Mon Mar 31 18:18:17 GMT 2025
PRIMARY
CAS
870603-16-0
Created by admin on Mon Mar 31 18:18:17 GMT 2025 , Edited by admin on Mon Mar 31 18:18:17 GMT 2025
PRIMARY
ChEMBL
CHEMBL3545027
Created by admin on Mon Mar 31 18:18:17 GMT 2025 , Edited by admin on Mon Mar 31 18:18:17 GMT 2025
PRIMARY
PUBCHEM
56931136
Created by admin on Mon Mar 31 18:18:17 GMT 2025 , Edited by admin on Mon Mar 31 18:18:17 GMT 2025
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
Related Record Type Details
ACTIVE MOIETY